Aditxt Inc Revenue Growth Rates (ADTX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Aditxt Inc   (NASDAQ: ADTX)
 

ADTX's Revenue Growth by Quarter and Year

Aditxt Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ADTX Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 0.01
FY 0.01

ADTXs Annual Revenue
Aditxt Inc 's Revenue in the fiscal year 2025 $ 0.00 millions
Aditxt Inc 's Revenue in the fiscal year 2024 $ 0.13 millions
Aditxt Inc 's Revenue in the fiscal year 2023 $ 0.65 millions
Aditxt Inc 's Revenue in the fiscal year 2022 $ 0.93 millions
Aditxt Inc 's Revenue in the fiscal year 2021 $ 0.11 millions




ADTX Revenue first quarter 2024 Y/Y Growth Comment
Aditxt Inc in the first quarter 2024 achieved Revenue of $ 0.01 millions compare to recorded in same quarter a year ago.

According to the results reported in the first quarter 2024, Aditxt Inc achieved the best Revenue growth in Major Pharmaceutical Preparations industry. While Aditxt Inc ' s Revenue no change of 0% ranks overall at the positon no. in the first quarter 2024.


ADTX Revenue ( Y/Y Growth %) 2024
 2023 2022 2021
4th Quarter December - - - -57.89 %
3rd Quarter September - - -91.67 % -62.5 %
2nd Quarter June - - -81.82 % 4.76 %
1st Quarter March - - -63.64 % 4.76 %
FY   - - -79.69 % -

Financial Statements
Aditxt Inc 's first quarter 2024 Revenue $ 0.01 millions ADTX's Income Statement
Aditxt Inc 's first quarter 2023 Revenue $ 0.00 millions Quarterly ADTX's Income Statement


ADTX Revenue (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
4th Quarter December - - - -33.33 %
3rd Quarter September - - -75 % -45.45 %
2nd Quarter June - - -50 % 0 %
1st Quarter March - - 0 % 15.79 %
FY (Year on Year)   - - -79.69 % -


Back to ADTX Growth rate Comparisons >> Back to ADTX Growth rate Comparisons >>


Revenue first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
(Mar 31 2024)   (Jun 30 2024)
Revenue first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
(Mar 31 2024)   (Jun 30 2024)

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Aditxt Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ADTX's I. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ADTX's I. Quarter Q/Q Revenue Comment


Aditxt Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)		 12 Months Ending
(Mar 31 2025)
Cumulative Revenue 12 Months Ending $ 0.01 $ 0.00 $ 0.01 $ 0.01 $ 0.06
Y / Y Revenue Growth (TTM) -73.95 % -97.61 % -97.27 % -96.36 % -89.09 %
Year on Year Revenue Growth Overall Ranking # 3381 # 3344 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) 350 % -44.83 % -51.67 % -78.29 % -58.74 %
Seq. Revenue Growth (TTM) Overall Ranking # 1915 # 1895 # 0 # 1765 # 2105


Cumulative Revenue growth Comment
Aditxt Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Dec 31 2025. If the fiscal year would end in Mar 31 2026, Aditxt Inc 's annual Revenue drop would be -73.95% year on year to $0 millions.

In the Healthcare sector 468 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3344 to 3381.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 126
Healthcare Sector # 469
Overall # 3381

Revenue TTM Y/Y Growth Statistics
High Average Low
-31.08 %
 -40.62 %
-50.16 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 126
Sector # 334
S&P 500 # 1915
Cumulative Revenue growth Comment
Aditxt Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Dec 31 2025. If the fiscal year would end in Mar 31 2026, Aditxt Inc 's annual Revenue drop would be -73.95% year on year to $0 millions.

In the Healthcare sector 468 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3344 to 3381.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 126
Healthcare Sector # 469
Overall # 3381

Revenue TTM Y/Y Growth Statistics
High Average Low
-31.08 %
-40.62 %
-50.16 %
 






Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ADTX's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Mar 31 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2026
Trisalus Life Sciences Inc -0.03%$ -0.035 millions
Adma Biologics Inc -0.30%$ -0.304 millions
Vaso Corporation-0.54%$ -0.545 millions
60 Degrees Pharmaceuticals Inc -0.92%$ -0.922 millions
Cytosorbents Corporation-0.95%$ -0.945 millions
Conmed Corporation-1.31%$ -1.310 millions
Neuropace Inc -1.32%$ -1.316 millions
Bio techne Corp-1.35%$ -1.353 millions
Schrodinger Inc -1.62%$ -1.619 millions
United Therapeutics Corporation-1.62%$ -1.624 millions
Prokidney Corp -1.74%$ -1.739 millions
Sarepta Therapeutics Inc -1.89%$ -1.887 millions
Fortrea Holdings Inc -2.27%$ -2.272 millions
Ultragenyx Pharmaceutical Inc -2.36%$ -2.363 millions
Teladoc Health Inc -2.47%$ -2.467 millions
Fonar Corporation-2.55%$ -2.551 millions
Puma Biotechnology Inc -2.59%$ -2.593 millions
Coya Therapeutics Inc -2.61%$ -2.612 millions
10x Genomics Inc -2.76%$ -2.763 millions
Plus Therapeutics Inc -2.93%$ -2.927 millions
Infusystem Holdings Inc-2.97%$ -2.973 millions
Solventum Corporation-3.04%$ -3.043 millions
Milestone Scientific Inc -3.15%$ -3.153 millions
Organon and Co -3.50%$ -3.503 millions
Fulgent Genetics Inc -3.89%$ -3.894 millions
Igc Pharma Inc -3.94%$ -3.939 millions
Carlisle Companies Incorporated-3.99%$ -3.988 millions
Harvard Bioscience Inc -4.44%$ -4.437 millions
Castle Biosciences Inc -4.90%$ -4.897 millions
Prestige Consumer Healthcare Inc -4.95%$ -4.953 millions


About Aditxt Inc Revenue Growth Rates (ADTX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Aditxt Inc (CIK 1726711).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001213900-26-059562
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Aditxt Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.